Climb Bio, INC Form 4 insider transactions

RA Capital Management, L.P. and its affiliated funds have reported changes in beneficial ownership related to Climb Bio, Inc. (CLYM), including the acquisition of stock options.

Climb Bio, Inc. director Breanna Maurine Celebi reported the acquisition of a stock option for 70,284 shares.

Climb Bio, Inc. President and CEO Aoife Brennan reports significant stock transactions, including RSU vesting and a sale under a 10b5-1 plan.

RA Capital Management disclosed a stock option grant for 40,000 shares awarded to Dr. Andrew Levin for his service on the Climb Bio board.

Director Andrew David Levin was granted 40,000 stock options in Climb Bio, Inc. to be held for the benefit of RA Capital Management.

Director Kimberlee C. Drapkin was granted 40,000 stock options in Climb Bio, Inc. as part of a standard equity compensation arrangement.

Director Douglas E. Williams was granted 40,000 stock options in Climb Bio, Inc. as part of his compensation package.

Director Alexander Cumbo was granted 40,000 stock options in Climb Bio, Inc. as part of a standard equity compensation arrangement.

Director Stephen Basil Thomas was granted 40,000 stock options in Climb Bio, Inc. as part of a standard equity incentive.

Director Judith Dunn was granted 40,000 stock options in Climb Bio, Inc. with an exercise price of $10.55.

RA Capital Management acquired 2,106,000 pre-funded warrants in Climb Bio, Inc. to increase its beneficial ownership position.

Climb Bio, Inc. Director Thomas Stephen Basil sold 50,000 shares of common stock over two days in late February 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Climb Bio, Inc. President and CEO, Aoife Brennan, was granted 700,000 stock options with an exercise price of $3.81, vesting over four years.

Climb Bio, Inc.'s Chief Business Officer, Perrin Megan Wilson, was granted 300,000 stock options with an exercise price of $3.81.

Climb Bio, Inc.'s Chief Financial Officer, Susan Altschuller, was granted 142,500 stock options with an exercise price of $3.81, vesting over four years.

Climb Bio's Senior Vice President of Finance, Cindy Driscoll, was granted 100,000 stock options with an exercise price of $3.81, vesting over four years.

RA Capital Management, L.P. and its affiliated funds reported the purchase of 7,111 shares of Climb Bio, Inc. common stock at a weighted average price of $3.50 per share.

RA Capital Management, a significant shareholder and director at Climb Bio, Inc., reported an exchange of common stock for pre-funded warrants and subsequent purchases of additional common stock.

Climb Bio, Inc.'s Chief Financial Officer, Susan Altschuller, was granted 600,000 stock options with an exercise price of $1.97, vesting over four years.

Climb Bio, Inc. Director Stephen Basil Thomas acquired 100,375 shares of common stock through the vesting of restricted stock units after performance milestones were met.

Climb Bio, Inc.'s President and CEO, Aoife Brennan, reported the conversion of 68,750 Restricted Stock Units into common stock and a subsequent sale of 20,618 shares to cover tax withholding obligations.

Climb Bio, Inc. Director Stephen Basil Thomas converted 25,094 restricted stock units into common stock, increasing his direct beneficial ownership to 204,282 shares.

Climb Bio, Inc. has reported that Cindy Driscoll, Senior Vice President of Finance, was granted 200,000 stock options with an exercise price of $1.20 per share.

Climb Bio, Inc.'s SVP of Finance & CAO, Emily Pimblett, reported the conversion of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

RA Capital Management, a significant shareholder and director of Climb Bio, Inc., has reported the acquisition of 40,000 stock options for Climb Bio common stock at an exercise price of $1.29, granted to Dr. Andrew Levin, a Partner and Managing Director of RA Capital who serves on the Issuer's board.

Climb Bio, Inc. Director Kimberlee C Drapkin was granted 40,000 stock options with an exercise price of $1.29, as disclosed in a recent SEC Form 4 filing.

Climb Bio, Inc. Director and 10% Owner Alexander Cumbo was granted 40,000 stock options with an exercise price of $1.29, set to vest by June 2026 or the next annual meeting.

Climb Bio, Inc. Director Judith Dunn was granted 40,000 stock options with an exercise price of $1.29, vesting by June 2026 or the next annual meeting.

Climb Bio, Inc. Director Douglas E. Williams was granted 40,000 stock options with an exercise price of $1.29, aligning his interests with shareholder value.

Climb Bio, Inc. Director and 10% owner Andrew Levin reported the acquisition of 40,000 stock options with an exercise price of $1.29, which are held for the benefit of RA Capital Management funds.